SIGLEC1 and cancer: To overcome these issues, this study genetically fused mouse IFNα (mIFNα) with mannosylated mouse serum albumin (Man-MSA), and investigated the antitumor effects of the hybrid protein (Man-MSA-mIFNα) or its add-on effects with programmed death-ligand 1 (PD-L1) blockade.<h4>Methods</h4>To confirm the possibility of CD169<sup>+</sup> macrophage-mediated T cell priming, positional information about individual immune cells in LNs of cancer patients was obtained.